A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

Trial Profile

A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Brontictuzumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors OncoMed Pharmaceuticals
  • Most Recent Events

    • 06 Dec 2016 Results of safety and preliminanary efficacy (n=23) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 16 Sep 2016 Status changed from recruiting to completed.
    • 26 Feb 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top